Company Overview
  Fidaxomicin (OPT-80)
  Pruvel™ (prulifloxacin)
  Clostridium difficile infection (CDI)


  • Prulifloxacin
    Fact Sheet
    PDF


  • Prulifloxacin 002 Phase 3
    Prulifloxacin, a New Fluoroquinolone Treatment for Traveler’s Diarrhea, poster presented at the 49th ICAAC, September 2009
    Poster PDF


  • Prulifloxacin 001 Phase 3
    A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Prulifloxacin as Therapy for Traveler's Diarrhea, poster presented at the 48th ICAAC, October 2008
    Poster PDF


  • Prulifloxacin in vitro activity against 8 pathogens that cause Travelers' Diarrhea
    In Vitro Activity of Ulifloxacin (Active Metabolite of Prulifloxacin) Tested Against a Worldwide Collection of Pathogens Producing Traveler's Diarrhea, poster presented at the 47th ICAAC, an annual meeting of the American Society for Microbiology, September 2007
    Poster PDF


  • Prulifloxacin DD QC Ranges
    Proposed Disk Diffusion Quality Control Ranges for Ulifloxacin (Active Metabolite of Prulifloxacin) and Intermethod Comparison Using CLSI Methods, poster presented at the 47th ICAAC, an annual meeting of the American Society for Microbiology, September 2007
    Poster PDF


  • Prulifloxacin in vitro activity against enteric pathogens
    Profiling of Ulifloxacin, the active metabolite of Prulifloxacin, versus bacterial pathogens producing Traveler’s Diarrhea, poster presented at the 46th ICAAC, an annual meeting of the American Society for Microbiology, 2006
    Poster PDF